Novo Nordisk's $475-billion rise and fall as Wegovy-era gains wiped out

Feb 23 (Reuters) - Novo Nordisk shares slumped by more than 16% on Monday, wiping away the remaining gains brought by its blockbuster weight-loss drug Wegovy, after the drugmaker said its next-generation obesity drug CagriSema underperformed Eli Lilly's rival.

Why Novo Nordisk Stock Just Crashed

GLP-1 weight loss drug CagriSema may not be the salvation Novo Nordisk was hoping for.

Stocks to Watch Monday Recap: Diamondback, Netflix, Novo Nordisk, Lilly

The telehealth platform said it expects growth to continue this year, though its first quarter guidance [came in short](

Instant View: Novo's CagriSema setback may shift investor focus to M&A strategy, analysts say

Feb 23 () - Novo Nordisk's next-generation weight-loss drug CagriSema was less effective than Eli Lilly's Zepbound in a head-to-head trial, a fresh blow to the Danish drugmaker's efforts to reclaim
Pharmaceutical Technology

Novo Nordisk flags board members for re-election amid restructuring efforts

Three new members could join Novo’s council, which largely consists of recent appointees following a restructure in October 2025.

Novo Nordisk nominates Jan van de Winkel and Ramona Sequeira to board

COPENHAGEN, Feb 20 (Reuters) - Novo Nordisk said on Friday it would nominate Jan van de Winkel and Ramona Sequeira to its board of directors, the first additions since a shake-up at the Danish obesity drugmaker last year.